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Background: It is well documented that overt hypothyroidism is associated with adverse pregnancy
outcomes, but studies of subclinical hypothyroidism have demonstrated conﬂicting results.
Objective: Thyroid hormones are known to regulate mitochondrial function, and the aim of this study
was to examine the possible relationship of subclinical hypothyroidism and mitochondrial dysfunction to
adverse pregnancy outcomes in pregnant women.
Methods: Women in their third trimester of pregnancy (n ¼ 113) who did not receive thyroid medication
were included in this cross-sectional study. All participants were interviewed, and their thyroid status
was determined. All participants had concentrations of thyroid hormones (fT4 and tT3) within the
reference range. In addition to thyroid status, mitochondrial membrane potential (MMP) and reactive
oxygen species (ROS) were measured by ﬂow cytometry. To establish a reference range of MMP and ROS,
a group of euthyroid, nonpregnant women were used as euthyroid controls. Adverse pregnancy outcome
was deﬁned as preterm delivery, preeclampsia, placental abruption, Apgar score <7 points 1 minute after
birth, or postpartum hemorrhage.
Results: The prevalence of subclinical hypothyroidism among pregnant womenwas 17% (n ¼ 19), and the
number of overall adverse pregnancy outcomes was increased (p ¼ 0.02) compared with that in
euthyroid pregnant women. Preeclampsia, poor Apgar score, and postpartum hemorrhage were more
frequent in the subclinical hypothyroidism group than in the euthyroid group (p ¼ 0.04, p ¼ 0.001 and
p ¼ 0.03, respectively), and more women showed prolonged gestation and gave birth later than 41 weeks
of gestation than in the euthyroid group (p ¼ 0.04). Compared with euthyroid, nonpregnant controls, a
physiological upregulation of mitochondrial function was observed in euthyroid pregnant women. This
was impaired in pregnant women with subclinical hypothyroidism. Compared with euthyroid,
nonpregnant controls, pregnant women had increased ROS regardless of their thyroid status.
Conclusion: We speculate that the unfavorable effects on mitochondrial function in women with sub-
clinical hypothyroidism may be associated with higher prevalence of adverse pregnancy outcomes.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license. TPOAb, thyroid peroxidase antibody; fT4, free thyroxine; tT3, total triiodothyronine; TMRM, tetramethylrhodamine
ripheral blood mononuclear cells; MMP, mitochondrial membrane potential; carboxy-H2DCFDA, 5(6)-carboxy-2’-7’-
ge; BMI, body mass index.
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the same assays, and all nonpregnant euthyroid women had valuesSubclinical hypothyroidism is deﬁned as increased level of
thyroid-stimulating hormone (TSH) and levels of thyroid hormones
within the reference range. Subclinical hypothyroidism is the most
frequent thyroid disease during pregnancy, compared with overt
hypothyroidism and overt and subclinical hyperthyroidism [1].
Depending on the cut-off values used for the deﬁnition of sub-
clinical hypothyroidism, ethnicity, and study design, the reported
prevalence varies between 1.5% and 4% [2e5]. It is well documented
that overt hypothyroidism is associated with increased risk of ob-
stetric complications such as miscarriage, gestational hypertension,
preterm delivery, stillbirths, and perinatal deaths [6e8]. However,
although studies of maternal subclinical hypothyroidism have also
suggested a relation to adverse effects [9e11], this relation is not as
well established.
A number of cellular functions are regulated by thyroid hor-
mones, and one major function is that of mitochondrial energy
production and biogenesis [12]. Several studies have reported
impaired thyroid hormone-regulated mitochondrial function in
patients with subclinical hypothyroidism [13e15].
The aim of the present study was to examine pregnancy out-
comes in womenwith subclinical hypothyroidism, and the relation
to a possible mitochondrial dysfunction, as well as to examine
whether mitochondrial function was inﬂuenced by pregnancy.Material and methods
Women in their third trimester of pregnancy who consulted the
Department of Obstetrics, Naestved Hospital, Region Zealand,
Denmark, between June 2012 and January 2013 were included.
Women with known thyroid disease, diabetes, and those
receiving any medical treatment for thyroid disease were excluded.
In total, 115 pregnant women (all of Caucasian ethnicity) were
included. Two women were subsequently excluded because they
gave birth at home and their data were unavailable. The remaining
113 data sets were complete.
All participants were interviewed to ensure full investigation of
their obstetric history. Body mass index (BMI) before pregnancy
was obtained from general practitioner records.
All women were examined during the ﬁrst trimester, and
gestational age (GA) was determined by ultrasound. GA at delivery,
placental abruption, preeclampsia, cesarean section, postpartum
hemorrhage, Apgar score, birth weight, and any severe event
occurring during the period from inclusion in the study until de-
livery were obtained from hospital records.
Adverse pregnancy outcome was deﬁned as preterm delivery
(GA<37 weeks), preeclampsia, placental abruption, Apgar score<7
points 1 minute after birth, postpartum hemorrhage (>500 mL), or
delivery later than 41 weeks after gestation. Preeclampsia was
deﬁned as persistent blood pressure 140/90 mm Hg accompanied
by proteinuria >300 mg/24 h or þþ proteinuria determined by
urinary dipstick analysis (Multistix 7, Siemens Healthcare, Tarry-
town, NY, USA). The deﬁnition of adverse pregnancy outcome was
based on former studies of hypothyroidism during pregnancy, and
all criteria carry potential risks of increased mortality and
morbidity.
To ensure that the control group of age-matched, euthyroid,
nonpregnant women (n ¼ 42) had not consulted the hospital
regarding emergency or chronic disease, participants were
recruited from a population study performed at Naestved Hospital
during the same period [16]. The control group was included to
establish the normal reference range of mitochondrial membrane
potential (MMP) and production of reactive oxygen species (ROS).of TSH, thyroid peroxidase antibody (TPOAb), and thyroid hor-
mones within the reference ranges.
Biochemical variables
Measurements of TSH and thyroid hormones fT4 and tT3 were
performed using an electrochemical luminescent immunoassay
(Roche Cobas 6000, Basel, Switzerland). TPOAb was measured by
KRYPTOR antiTPOn (BRAHMS, Hennigsdorf, Germany), detection
limit 10 U/mL.
Normal values for thyroid hormones followed the standard
references used at the Central Laboratory of Naestved Hospital:
fT4 ¼ 10.0e26.0 pmol/L and tT3 ¼ 1.20e2.80 nmol/L. This reference
range also covers the trimester-speciﬁc alterations (decrease of fT4
and rise of tT3 within the reference range).
Subclinical hypothyroidism was deﬁned as raised serum con-
centration of TSH 3.40 mU/L (this cutoff value was chosen based
on recommendations from the testing laboratory at the hospital)
and thyroid hormones within the reference range. Thyroid perox-
idase antibody positivity was deﬁned by the cutoff value of TPOAb
>60 U/mL.
Measurement of mitochondrial function
MMP and ROS production were measured using ﬂow cytometry
as previously described [15,17,18]. In brief, peripheral blood
mononuclear cells (PBMC) were obtained from a freshly drawn
blood sample and stained with 0.1 mmol/L tetramethylrhodamine
methyl ester (TMRM) or 1 mM 5(6)-carboxy-2’-7’-dichlorodihy-
droﬂuoresceindiacetate (carboxy-H2DCFDA) (Invitrogen A/S,
Taastrup, Denmark). The cells were incubated in the dark for 30min
at room temperature for TMRM and at 37 C for carboxy-H2DCFDA.
The cells were chilled on ice and immediately measured by ﬂow
cytometry (Accuri C6, BD Biosciences, Franklin Lakes, NJ, USA). A
total of 20,000 leukocytes were acquired, and the lymphocytes
were identiﬁed on the forward- and side-scatter parameters.
The median TMRM and carboxy-H2DCFDA ﬂuorescence intensities
of PBMC were calculated using BD Accuri C6 software, and values
were given as relative emission (arbitrary units, a.u.). The intra-
assay variation of TMRM and carboxy-H2DCFDA measurements
was <12%.
Because of the time-consuming procedure of performing ﬂow
cytometry on fresh blood specimens, the number of participants
was limited.
Statistics
The Student’s t-test orManneWhitney test was used to compare
cases and controls. The ShapiroeWilk test was used to test
normality of the distribution of data, and the Wilcoxon signed-rank
test was used to compare paired data. The discontinuous variables
were compared using c2-test. The Spearman correlation coefﬁcient
was used to evaluate the correlation of the variables. A value of
p < 0.05 was considered statistically signiﬁcant. All statistical an-
alyses were performed using STATA version 11 for Windows (Sta-
taCorp, College Station, TX, USA).
Ethical considerations
The study was approved by the Regional Research Ethics Com-
mittee of Zealand, Denmark (Reg. no. RVK SJ-294). The clinical trial
registration at ClinicalTrial.gov is NCT01335802.
Figure 1. Reactive oxygen species. Flow cytometry analysis of reactive oxygen species
(ROS) in pregnant womenwith subclinical hypothyroidism (subhypo pregnant, n ¼ 19),
euthyroid pregnant women (n ¼ 94), and euthyroid non-pregnant women (controls,
n ¼ 42). All points represent median values and 25the75th percentiles (Manne
Whitney test).
Table 1
Clinical data of 113 pregnant women with or without subclinical hypothyroidism
and pregnancy outcome
Subclinical
hypothyroidism
Euthyroid p-value
n ¼ 19 (17%) n ¼ 94 (83%)
Characteristics
Age (years)
Mean (range) 30 (21e41) 29 (19e42) 0.33a
BMI before pregnancy (kg/m2)
Mean (range) 28 (22e46) 26 (17e44) 0.32b
Parity ¼ 0 (n) 10 (53%) 43 (46%) 0.58c
Complications
Preeclampsia (n) 6 (32%) 12 (13%) 0.04c
Preterm delivery GA <37
(n)
2 (5%) 9 (10%) 0.90c
Delivery GA >41 (n) 7 (37%) 15 (16%) 0.04c
Placental abruption (n) 0 (0%) 1 (1%) 0.65c
Caesarean section (n) 8 (42%) 37 (39%) 0.82c
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clusion in the study, and the study conformed to the principles of
the Declaration of Helsinki.
Results
Euthyroid pregnant women versus euthyroid nonpregnant women
The trimester-speciﬁc fT4 decreased and tT3 increased, although
both hormones remained within the reference range. There was no
difference in TSH between the pregnant and nonpregnant euthy-
roid groups.
The mitochondrial parameters were also signiﬁcantly different
in the pregnant and nonpregnant euthyroid groups, which may
represent a physiological adaptation to pregnancy. Both ROS
(p ¼ 0.002) (Figure 1) and MMP (p ¼ 0.003) (Figure 2) were
signiﬁcantly increased in the euthyroid pregnant women, which inFigure 2. Mitochondrial membrane potential. Flow cytometry analysis of mitochon-
drial membrane potential (MMP) in pregnant women with subclinical hypothyroidism
(subhypo pregnant, n ¼ 19), euthyroid pregnant women (n ¼ 94), and euthyroid non-
pregnant women (controls, n ¼ 42). All points represent mean values and standard
errors (Student’s t-test).our opinion represents a physiological adaptation to pregnancy and
to our knowledge has not been reported previously.
Pregnant women with subclinical hypothyroidism versus euthyroid
pregnant women
Nineteen of the 113 pregnant women (17%) had subclinical hy-
pothyroidism. The mean gestational age at inclusion was 257 days.
As can be seen in Table 1, no differences were present between the
subclinical hypothyroidism group and the euthyroid group
regarding age, prepregnancy BMI, or parity. Signiﬁcantly higher
numbers of overall adverse pregnancy outcomes were observed
among women with subclinical hypothyroidism than among
euthyroid women (p ¼ 0.02).
Table 1 shows that the adverse outcomes were attributed to
preeclampsia, postpartum hemorrhage, and higher numbers of
newborns with Apgar score <7 points 1 minute after birth. In
addition, women with subclinical hypothyroidism had higher fre-
quencies of prolonged gestation (gestational age >41 weeks at
delivery). In this study, no differences were observed in the number
of preterm deliveries, caesarean sections, or birth weights related to
gestational age.Postpartum hemorrhage
>500 mL (n)
10 (53%) 26 (28%) 0.03c
Apgar <7/1 min (n) 5 (26%) 4 (4%) 0.001c
Birth weight (g)
Mean (range) 3450 (1201e4500) 3360 (1435e4700) 0.39b
Neonatal intensive care
unit (n)
4 (21%) 11(12%) 0.27c
Adverse pregnancy
outcome (n)
15 (79%) 47 (50%) 0.02c
Biochemical
TSH (mU/L)
Median (IQR) 4.2 (3.6e5.6) 1.8 (1.1e2.3) <0.001b
tT3 (nmol/L)
Median (IQR) 2.67 (2.23e3.20) 2.70 (2.34e2.92) 0.80b
fT4 (pmol/L)
Median (IQR) 11.4 (10.5e12.9) 11.2 (10.2e12.8) 0.71b
TPOAb positive (n) 1 (5%) 7 (7%) 0.74c
Subclinical hypothyroidism was deﬁned by TSH (thyroid stimulating
hormone) 3.4 mU/L and levels of tT3 (total triiodothyronine) and fT4 (free
thyroxine) within the reference range. TPOAb positivity was deﬁned by thyroid
peroxidase antibody >60 U/mL. Values are mean (range) or median (IQR: inter-
quartile range).
a Student’s t-test was used to compare age as these are considered normally
distributed data.
b ManneWhitney test was used to compare biochemical values, BMI and birth
weight.
c Frequencies are noted as numbers (percent) and c2-test was used to
compare data.
Boldface indicates p < 0.05.
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Pregnant women with subclinical hypothyroidism had signiﬁ-
cantly decreased MMP (Figure 2) compared with that of euthyroid
pregnant women (p ¼ 0.037), whereas no difference in ROS was
observed between these two groups (p ¼ 0.93) (Figure 1).
The relationship between tT4 and the mitochondrial parameters
MMP and ROS was examined in euthyroid pregnant women and
pregnant women with subclinical hypothyroidism. A signiﬁcant
correlation between MMP of TMRM-stained PBMCs and fT4
(r ¼ 0.25, p ¼ 0.03) and of ROS and fT4 (r ¼ 0.28, p ¼ 0.018) was
observed in the euthyroid pregnant group, but no correlation was
found in women with subclinical hypothyroidism (r ¼ 0.29,
p ¼ 0.29 and r ¼ 0.07, p ¼ 0.78, respectively).
Discussion
In the present study we observed an association between sub-
clinical hypothyroidism during the third trimester of pregnancy and
adverse pregnancy outcomes. Mitochondrial function was altered
during normal euthyroid pregnancy compared with that in
nonpregnant women. However, this pregnancy-induced alteration
was not seen in women with subclinical hypothyroidism.
The relation between subclinical hypothyroidism and adverse
pregnancy outcomes has recently been a subject of discussion in
the literature. Cleary-Goldman et al. concluded that there was no
consistent pattern of adverse pregnancy outcomes in subclinical
hypothyroid women [19]. In contrast, Wilson et al. reported that
women with subclinical hypothyroidism identiﬁed during preg-
nancy had an increased risk of severe preeclampsia [20]. Our results
also indicate an association between subclinical hypothyroidism
and adverse pregnancy outcomes, although the number of partic-
ipants in the present study necessarily was smaller than that used
by Wilson et al. because of the comprehensive mitochondrial
analyses.
Davis et al. reported a higher prevalence of postpartum hem-
orrhage in womenwith overt as well as subclinical hypothyroidism
[21], but other studies found no association [22,23]. We observed a
signiﬁcantly higher number of postpartum hemorrhages in women
with subclinical hypothyroidism than in euthyroid women. In
addition, the number of women with prolonged gestation (gesta-
tional age >41 weeks at delivery) was signiﬁcantly higher in the
group with subclinical hypothyroidism. The risk of maternal mor-
tality and complications during birth is increased in post-term
pregnancies independent of thyroid function [24]. Therefore, sub-
clinical hypothyroidism carries an additional risk of birth compli-
cations due to prolonged gestation.
This study of an ethnically homogenous study population
(Caucasian) found a higher prevalence of subclinical hypothyroid-
ism than previously reported despite the fact that women with
previous or present thyroid disease and those on antihypothyroid
or antihyperthyroid medication were excluded from the study. In
addition, we observed a higher frequency of adverse pregnancy
outcomes such as preeclampsia, postpartum hemorrhage, poor
Apgar score, and prolonged gestation in women with subclinical
hypothyroidism. Finally, we present a possible link between the
higher frequency of adverse pregnancy outcomes in women with
subclinical hypothyroidism and changes in mitochondrial function.
The prevalence of subclinical hypothyroidism in pregnant women
in their third trimester was 17%, which is higher than that found in
other studies, which may be related to the mild iodine deﬁciency in
Eastern Denmark that has been reported previously [25].
The cutoff value of TSH used in this study was 3.4 mU/L. How-
ever, because some recent studies have suggested use of the cutoff
value 3.0 mU/L in third-trimester pregnant women, the data setwas recalculated using this value. Although the prevalence of sub-
clinical hypothyroidism was increased, adverse outcomes and
mitochondrial function were not signiﬁcantly changed. In consid-
eration of this fact and because the department has previously
conducted a number of studies of subclinical hypothyroidism using
a cutoff value for TSH of 3.4 mU/L, it seems appropriate to maintain
this cutoff value also in the present study. The higher prevalence of
subclinical hypothyroidism found here may be caused by the fact
that the inclusion took place at the department of obstetrics from
patients who were visiting the department because they had
symptoms of disease or other signs that needed evaluation by an
obstetrician.
MMP reﬂects the functional state of mitochondria, as it is a
driving force for ATP-synthesis. ROS are mainly generated by elec-
tron leaks from the electron transport chain and depend onMMP, as
more ROS are produced when MMP is increased [26,27].
In the present study we observed an increase in ROS in euthy-
roid pregnant women compared with euthyroid nonpregnant
controls (p ¼ 0.002). Since the increase is similar for euthyroid
pregnant and subclinically hypothyroid pregnant women, we re-
gard this result as a pregnancy-driven physiological regulation of
mitochondrial function. Physiological adaptations in euthyroid
pregnant women compensate for the increased ROS by increasing
the MMP and thereby ensuring sufﬁcient ATP production. Pregnant
women with subclinical hypothyroidism did not present the ex-
pectedMMP rise comparedwith that in euthyroid pregnant women
and showed a signiﬁcantly lower MMP. This observation suggests
that the cells may not be able to compensate for the increased ROS
and that ATP production may be insufﬁcient. This conclusion is
supported by the lack of correlation between fT4 and MMP in
subclinical hypothyroid pregnant women and may provide a link to
the adverse pregnancy outcomes observed.
Thyroid hormone regulates MMP [17]. In euthyroid pregnant
women, we observed the expected inverse correlation between fT4
and the mitochondrial parameters MMP and ROS, which is likely
caused by the fact that a product of deiodination of T4 (3’,5’-diio-
dothyronine) stimulates MMP [17]. By contrast, no correlation was
observed in the group with subclinical hypothyroidism, suggesting
an impaired thyroid hormone regulation of the mitochondrial
balance between ATP and ROS production.
Conclusion
In conclusion, we observed a physiological upregulation of
mitochondrial function in euthyroid pregnant women, which was
impaired in pregnant women with subclinical hypothyroidism. We
hypothesize that unfavorable effects on mitochondrial function in
women with subclinical hypothyroidism could be the link to the
higher prevalence of adverse pregnancy outcomes due to insufﬁ-
cient ATP production.
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